Abstract: Pharmaceutical composition for inhalation, containing as active ingredient effective amounts of salmeterol or a physiologically salt of salmeterol or a solvate thereof, and budesonide or a therapeutically salt of budesonide or a solvate thereof, wherein the molecular ratio of salmeterol component to budesonide component is in the range 1:2 to 1:50, together with a pharmaceutically acceptable carrier.
Type:
Application
Filed:
September 13, 2007
Publication date:
May 8, 2008
Applicant:
GALEPHAR M/F
Inventors:
Arthur Deboeck, Philippe Baudier, Francis Vanderbist
Abstract: A controlled Release Pharmaceutical composition comprising an effective amount of Pravastatin and Fenofibrate, characterised in that the difference, in absolute value, between the times of maximal concentration (Tmax) of Pravastatin and Fenofibric acid is not less than 1.5 hours upon administration with food to humans.
Type:
Application
Filed:
February 6, 2006
Publication date:
April 26, 2007
Applicant:
GALEPHAR M/F
Inventors:
Arthur Deboeck, Philippe Baudier, Francis Vanderbist, Antonio Sereno
Abstract: pharmaceutical combination or composition for inhalation a fixed combination (A) L-lysine N-acetylcysteinate and (B) a bronchodilator agent for simultaneous, sequential or separate administration by inhalation in the treatment of an inflammatory or obstructive respiratory disease.
Type:
Application
Filed:
August 6, 2003
Publication date:
March 29, 2007
Applicant:
GALEPHAR M/F
Inventors:
Arthur Deboeck, Philippe Baudier, Francis Vanderbist
Abstract: The present invention is directed to the discovery of the anti-inflammatory properties of basic amino salts of acetylcysteine when administered directly to the lungs and/or the nose. This observed inflammation reduction in the lungs and/or the nasal cavity is confirmed by the diminution of at least one of the following inflammatory markers IL_6 and IL_8 and/or the increase in the lungs and/or the nasal cavity of the anti-inflammatory markers IL_10. The present invention also discloses pharmaceutical compositions for pulmonary and/or nasal administration of basic amino salts of acetylcysteine characterised that they have anti-inflammatory properties and may be useful to treat inflammatory lung and/or nasal conditions found in illnesses such as COPD, asthma, cystic fibrosis and the like.
Type:
Application
Filed:
December 13, 2004
Publication date:
July 14, 2005
Applicant:
Galephar Pharmaceutical Research, Inc.
Inventors:
Arthur Deboeck, Francis Vanderbist, Phillippe Baudier
Abstract: The present invention relates to a once daily extended release pharmaceutical preparation of Tramadol or its acceptable pharmaceutical salts.
Type:
Application
Filed:
April 11, 2002
Publication date:
July 31, 2003
Applicant:
GALEPHAR PHARMACEUTICAL RESEARCH, INC.
Inventors:
Arthur M. Deboeck, Francis Vanderbist, Antonio Sereno
Abstract: A pharmaceutical composition is provided for treating hyperlipidemia or hypercholesterolemia or both in a mammal, which contains an effective amount of each of fenofibrate and an excipient containing one or more polyglycolyzed glycerides.
Type:
Grant
Filed:
January 10, 1995
Date of Patent:
August 13, 1996
Assignee:
Galephar P.R. Inc.
Inventors:
Arthur Deboeck, Paul Maes, Phillipe R. Baudier
Abstract: An extended-release galenical form of Diltiazem or a pharmaceutically acceptable salt thereof, which comprises beads containing said Diltiazem or a pharmaceutically acceptable salt thereof as an active ingredient and a wetting agent, said beads being coated with a microporous membrane comprising at least a water-soluble or water-dispersible polymer or copolymer and a pharmaceutically acceptable adjuvant.
Abstract: An extended-release galenical form of Diltiazem or a pharmaceutically acceptable salt thereof, which comprises beads containing said Diltiazem or a pharmaceutically acceptable salt thereof as an active ingredient and a wetting agent, said beads being coated with a microporous membrane comprising at least a water-soluble or water-dispersible polymer or copolymer and a pharmaceutically acceptable adjuvant.
Abstract: Water-soluble acetylcysteine salts, useful as mucolytic agents, consisting of reaction products of acetylcysteine with at least one basic amino-acid, the latter being preferably selected from the group comprising arginine, lysine, histidine, ornithine and glycine.